Rejuvenate Bio develops one-shot gene therapies aimed at addressing aging and chronic disease by reprogramming the body's function. The company originated from the laboratory of George Church at Harvard Medical School and is led by scientists with backgrounds in genetics, synthetic biology, engineering, and gene therapy. Its platform aims to restore youthful biology in both humans and companion animals.
The company operates two core platforms. Platform 1 is a liver-directed gene therapy that delivers the FGF21 gene via an AAV8 vector to the liver, with the goal of restoring youthful FGF21 levels to regulate metabolism, inflammation, and tissue repair. In preclinical models, this approach has shown reversal of cardiac damage and improvement in metabolic function. Platform 2 centers on epigenetic reprogramming, which resets gene expression without altering DNA, by selectively activating transcription factors. In preclinical models, this approach has been associated with extended remaining lifespan, improved physical performance, and rejuvenation of nerve and vision function.
Rejuvenate Bio has developed a proprietary high-yield manufacturing system that reduces production costs, with doses produced at under $100. The company pursues a dual-market strategy that leverages animal health partnerships to fund research and manufacturing while generating milestone and royalty streams, and uses data and manufacturing efficiencies to support its human programs. Notable animal health partnerships include multi-year development and commercialization agreements with Phibro and Protect Animal Health, which provide near-term inflows and long-term royalty potential.
Current indicators include more than $130 million in contracted development and commercial milestone payments, along with cumulative payments and in-kind services from partners. Royalties on partner sales are expected to begin in the future as programs reach commercial milestones. The business model emphasizes rapid pipeline expansion across cardiovascular, metabolic, and neurodegenerative diseases, with a focus on translating animal data to human programs to accelerate readouts and reduce capital needs. The company notes progress toward cash flow positivity through its capital-efficient framework and animal-human program integration. Recognized by Harvard Business School and MIT Technology Review for pioneering work in reversing aging and extending healthspan, Rejuvenate Bio is led by founders Daniel Oliver and Dr. Noah Davidsohn, who collaborate with scientists and advisors from top institutions to advance regenerative medicine.